Hyperphosphatemia and Cardiovascular Disease

作者全名："Zhou, Chao; Shi, Zhengyu; Ouyang, Nan; Ruan, Xiongzhong"

作者地址："[Zhou, Chao; Shi, Zhengyu] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China; [Ouyang, Nan] Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing, Peoples R China; [Ruan, Xiongzhong] Univ Coll London UCL, Med Sch, Ctr Nephrol, John Moorhead Res Lab, London, England; [Ruan, Xiongzhong] Chongqing Med Univ, Affiliated Hosp 2, Ctr Lipid Res, Chongqing, Peoples R China; [Ruan, Xiongzhong] Chongqing Med Univ, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis, Minist Educ,Inst Viral Hepatitis,Dept Infect Dis, Chongqing, Peoples R China"

通信作者："Ouyang, N (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing, Peoples R China.; Ruan, XZ (corresponding author), Univ Coll London UCL, Med Sch, Ctr Nephrol, John Moorhead Res Lab, London, England.; Ruan, XZ (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Ctr Lipid Res, Chongqing, Peoples R China.; Ruan, XZ (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis, Minist Educ,Inst Viral Hepatitis,Dept Infect Dis, Chongqing, Peoples R China."

来源：FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY

ESI学科分类：MOLECULAR BIOLOGY & GENETICS

WOS号：WOS:000629966900001

JCR分区：Q1

影响因子：5.5

年份：2021

卷号：9

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：phosphate; cardiovascular disease; vascular calcification; cardiac valvular calcification; atherosclerosis; left ventricular hypertrophy; myocardial fibrosis; hypertension

摘要："Hyperphosphatemia or even serum phosphate levels within the ""normal laboratory range"" are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of hypertension, vascular calcification, cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy and myocardial fibrosis by distinct mechanisms. Therefore, phosphate is considered as a promising therapeutic target to improve the cardiovascular outcome in CKD patients. The current therapeutic strategies are based on dietary and pharmacological reduction of serum phosphate levels to prevent hyperphosphatemia in CKD patients. Large randomized clinical trials with hard endpoints are urgently needed to establish a causal relationship between phosphate excess and cardiovascular disease (CVD) and to determine if lowering serum phosphate constitutes an effective intervention for the prevention and treatment of CVD."

基金机构："National Key R&D Program of China [2018YFC1312700]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81500341, 32030054]; Chongqing Science and Technology CommissionNatural Science Foundation Project of CQ CSTC [cstc2018jcyjAX0134, cstc2020jcyj-msxmX0304, cstc2020jcyj-msxmX0152]; Moorhead Trust"

基金资助正文："This work was supported by National Key R&D Program of China (2018YFC1312700), National Natural Science Foundation of China (Nos. 81500341 and 32030054), Chongqing Science and Technology Commission (Nos. cstc2018jcyjAX0134, cstc2020jcyj-msxmX0304, and cstc2020jcyj-msxmX0152) and Moorhead Trust."